Auph short interest.

Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ...Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...Find out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... Short Interest 17.19M 11/15/23 % of Float ...

Meanwhile, Jefferies analyst Maury Raycroft, with a Buy rating on Aurinia ( AUPH ), has cut the per share target to $29 from $34 to imply a premium of ~142% to the last close. Raycroft attributes ...Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...

Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to Cover Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2. Change versus previous monthThe 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover.

Jul 18, 2023 · Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ... May 11, 2023 · AUPH is currently averaging 3,052,205 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …Short Interest - MarketWatchAUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...

Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of Float

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) d

316 K. 119 K. +166%. Loading... Stock Performance by Trading Session. Trading Session Volume Relative to Daily Average. View statistical stock analysis for Aurinia Pharmaceuticals - Common Shares (AUPH). Choose from a list of different historical perspectives such as intraday stock behavior, gap up moves, gap down moves, large …WebExhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ...Hudbay Minerals (TSE:HBM – Get Rating) (NYSE:HBM) had its price target raised by BMO Capital Markets from C$14.00 to C$15.00 in a research note released on Friday, BayStreet.CA reports. Other equities analysts also recently issued research reports about the company. National Bankshares upped their price objective on Hudbay Minerals …WebSep 27, 2023 · Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ... We would like to show you a description here but the site won’t allow us.That beat AUPH stock analysts' estimate for $22 million, according to FactSet. Per-share losses were 25 cents, narrower than expectations for 27 cents. Still, AUPH stock fell to its lowest point ...Web

Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas …Which Aurinia Pharmaceuticals insiders have been selling company stock? The following insiders have sold AUPH shares in the last 24 months: David R.W. Jayne ($98,333.58), Joseph M Miller ($100,986.24), Joseph P Hagan ($2,877.76), Peter Greenleaf ($292,785.00), and Stephen P Robertson ($173,453.88). How much insider selling is …Learn more about AUPH stock here. Skip to content. Explore Alpha Picks; ... Interest income rose to $3.8 million due to higher yields from increased interest rates. ... cash equivalents, and short ...Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dAurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...AUPH has no debt and, even better, 400 millions in cash. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for the end of the year (40-50 millions) with great expectations for the next years (200 in 2022, 400 in 2023, sales peak at 1.5 billions) ... The short interest. Since the FDA Approval in Jan 2021, the stock ...Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Business, Economics, and Finance. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. CryptoInstitutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQ 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the ...AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...Jun 30, 2023 · Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...

E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWeb

The 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover.

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...Get the latest SCYNEXIS Inc (SCYX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.M&A season started some weeks ago with Trilium / Pfizer, Sanofi bought Kadmon, etc... AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared a couple of weeks ago on different websites, about a 35+ acquisition by a big pharma, it was later asked to be removed by the company from Benzinga. The short interest In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...Aurinia Pharmaceuticals (AUPH) Short Interest. Company Profile Short interest 3 months. Data from FINRA. Short interest. Days to cover, using 30-day avg volume. Short ratio, using same-day volume. Volume. Short volume. Total volume. Stock price. Short ownership 3 …Mar 24, 2023 · AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ... ... short-term outlook for biotechnology or pharmaceuticals companies.” The top ... interest in any company mentioned in this article. Keep reading...Show less.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...Hudbay Minerals (TSE:HBM – Get Rating) (NYSE:HBM) had its price target raised by BMO Capital Markets from C$14.00 to C$15.00 in a research note released on Friday, BayStreet.CA reports. Other equities analysts also recently issued research reports about the company. National Bankshares upped their price objective on Hudbay Minerals …WebAUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR). Instagram:https://instagram. invest in watchesbest forex broker in usgrocery delivery free trialoanda vs ig Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, profile. ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas Short Interest. 0.Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million. stock iwmcetera securian Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company's stock are sold short. View Anebulo Pharmaceuticals' Short Interest. starter kits for growing weed Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ...Mar 24, 2023 · AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ... Short Interest : 17.19M: Short Previous Month : 17.28M: Short % of Shares Out : 11.97%: Short % of Float : 12.21%: Short Ratio (days to cover) 11.64